Cybin (NASDAQ:HELP) Stock Price Down 5.5% – Should You Sell?

Cybin Inc. (NASDAQ:HELP)’s share price fell 5.5% on Thursday . The company traded as low as $12.80 and last traded at $12.9250. Approximately 495,796 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 1,192,716 shares. The stock had previously closed at $13.68.

Key Stories Impacting Cybin

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: Heavy insider buying signals management confidence. Insiders Paul Glavine and Eric H. L. So collectively purchased 385,000 shares for approximately $4.55 million across transactions from August 31 through September 4. The purchases increased each insider’s existing position by more than 2%. Cybin insider trading report
• Positive Sentiment: Analyst sentiment and price targets are broadly bullish. The company has a reported consensus “Buy” rating and an average price target of $48.60, well above recent trading levels. TD Cowen recently raised its target to $62, while Wells Fargo initiated coverage with an “Overweight” rating and a $16 target. Cybin analyst and insider report
• Positive Sentiment: Upcoming investor conferences may increase visibility. CEO Michael Halstead is scheduled to participate in fireside chats at the H.C. Wainwright conference on September 14 and the Morgan Stanley Global Healthcare Conference on September 16. Investors may look for updates on HLP003, a Phase 3 major-depressive-disorder candidate, and HLP004, a Phase 2 generalized-anxiety-disorder candidate. Helus Pharma Morgan Stanley conference announcement
• Neutral Sentiment: The company is now using the Helus Pharma commercial name. The rebranding could improve visibility for its mental-health programs, but the events themselves do not represent new clinical data or regulatory approvals.
• Negative Sentiment: Cybin remains loss-making and clinically speculative. Its latest quarterly loss missed analyst expectations, with analysts forecasting a larger full-year loss. HLP003 and HLP004 still require successful trials and regulatory approval, and the company cautions that efficacy has not yet been confirmed.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HELP. Wells Fargo & Company assumed coverage on shares of Cybin in a report on Monday, July 27th. They set an “overweight” rating and a $16.00 price objective on the stock. Wall Street Zen upgraded Cybin from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Finally, TD Cowen raised their price objective on Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $48.60.

Cybin Stock Performance

The firm has a market cap of $975.75 million, a price-to-earnings ratio of -4.26 and a beta of 0.63. The business’s 50-day moving average is $9.70 and its 200-day moving average is $6.81.

Cybin (NASDAQ:HELP) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Equities research analysts expect that Cybin Inc. will post -2.95 EPS for the current fiscal year.

Insider Buying and Selling

In other Cybin news, insider Paul Glavine bought 100,000 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were bought at an average price of $11.78 per share, for a total transaction of $1,178,000.00. Following the completion of the acquisition, the insider owned 4,171,252 shares of the company’s stock, valued at approximately $49,137,348.56. This trade represents a 2.46% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Eric H. L. So bought 100,000 shares of the stock in a transaction dated Friday, September 4th. The stock was acquired at an average price of $12.09 per share, with a total value of $1,209,000.00. Following the completion of the purchase, the insider owned 4,365,014 shares of the company’s stock, valued at $52,773,019.26. This represents a 2.34% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 385,000 shares of company stock worth $4,551,100. 15.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HELP. Osaic Holdings Inc. increased its position in Cybin by 46.7% in the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock valued at $63,000 after acquiring an additional 2,400 shares in the last quarter. AXQ Capital LP acquired a new position in shares of Cybin during the second quarter worth approximately $75,000. Bank of America Corp DE lifted its position in shares of Cybin by 66.8% during the second quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after purchasing an additional 11,790 shares in the last quarter. Pale Fire Capital SE bought a new stake in shares of Cybin during the second quarter valued at approximately $1,015,000. Finally, Millennium Management LLC grew its stake in shares of Cybin by 1,388.5% during the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock valued at $8,414,000 after purchasing an additional 959,448 shares during the last quarter. Institutional investors and hedge funds own 17.94% of the company’s stock.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.